Global Antisense Oligonucleotide Therapies Market Insights, Forecast to 2029
This report presents an overview of global market for Antisense Oligonucleotide Therapies market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Antisense Oligonucleotide Therapies, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antisense Oligonucleotide Therapies, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Antisense Oligonucleotide Therapies revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Antisense Oligonucleotide Therapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Antisense Oligonucleotide Therapies revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Ionis Pharmaceuticals, Sarepta Therapeutics and Nippon Shinyaku, etc.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Antisense Oligonucleotide Therapies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antisense Oligonucleotide Therapies companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antisense Oligonucleotide Therapies revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
This report researches the key producers of Antisense Oligonucleotide Therapies, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antisense Oligonucleotide Therapies, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Antisense Oligonucleotide Therapies revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Antisense Oligonucleotide Therapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Antisense Oligonucleotide Therapies revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Ionis Pharmaceuticals, Sarepta Therapeutics and Nippon Shinyaku, etc.
By Company
- Ionis Pharmaceuticals
- Sarepta Therapeutics
- Nippon Shinyaku
- Without GalNAc-conjugated
- With GalNAc-conjugated
- Genetic Disease
- Cancer
- Cardiovascular Diseases
- Other
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East, Africa, and Latin America
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Antisense Oligonucleotide Therapies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antisense Oligonucleotide Therapies companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antisense Oligonucleotide Therapies revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Without GalNAc-conjugated
1.2.3 With GalNAc-conjugated
1.3 Market by Application
1.3.1 Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Antisense Oligonucleotide Therapies Market Perspective (2018-2029)
2.2 Global Antisense Oligonucleotide Therapies Growth Trends by Region
2.2.1 Antisense Oligonucleotide Therapies Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Antisense Oligonucleotide Therapies Historic Market Size by Region (2018-2023)
2.2.3 Antisense Oligonucleotide Therapies Forecasted Market Size by Region (2024-2029)
2.3 Antisense Oligonucleotide Therapies Market Dynamics
2.3.1 Antisense Oligonucleotide Therapies Industry Trends
2.3.2 Antisense Oligonucleotide Therapies Market Drivers
2.3.3 Antisense Oligonucleotide Therapies Market Challenges
2.3.4 Antisense Oligonucleotide Therapies Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Antisense Oligonucleotide Therapies by Players
3.1.1 Global Antisense Oligonucleotide Therapies Revenue by Players (2018-2023)
3.1.2 Global Antisense Oligonucleotide Therapies Revenue Market Share by Players (2018-2023)
3.2 Global Antisense Oligonucleotide Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Antisense Oligonucleotide Therapies, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Antisense Oligonucleotide Therapies Market Concentration Ratio
3.4.1 Global Antisense Oligonucleotide Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense Oligonucleotide Therapies Revenue in 2022
3.5 Global Key Players of Antisense Oligonucleotide Therapies Head office and Area Served
3.6 Global Key Players of Antisense Oligonucleotide Therapies, Product and Application
3.7 Global Key Players of Antisense Oligonucleotide Therapies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 ANTISENSE OLIGONUCLEOTIDE THERAPIES BREAKDOWN DATA BY TYPE
4.1 Global Antisense Oligonucleotide Therapies Historic Market Size by Type (2018-2023)
4.2 Global Antisense Oligonucleotide Therapies Forecasted Market Size by Type (2024-2029)
5 ANTISENSE OLIGONUCLEOTIDE THERAPIES BREAKDOWN DATA BY APPLICATION
5.1 Global Antisense Oligonucleotide Therapies Historic Market Size by Application (2018-2023)
5.2 Global Antisense Oligonucleotide Therapies Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Antisense Oligonucleotide Therapies Market Size (2018-2029)
6.2 North America Antisense Oligonucleotide Therapies Market Size by Type
6.2.1 North America Antisense Oligonucleotide Therapies Market Size by Type (2018-2023)
6.2.2 North America Antisense Oligonucleotide Therapies Market Size by Type (2024-2029)
6.2.3 North America Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
6.3 North America Antisense Oligonucleotide Therapies Market Size by Application
6.3.1 North America Antisense Oligonucleotide Therapies Market Size by Application (2018-2023)
6.3.2 North America Antisense Oligonucleotide Therapies Market Size by Application (2024-2029)
6.3.3 North America Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
6.4 North America Antisense Oligonucleotide Therapies Market Size by Country
6.4.1 North America Antisense Oligonucleotide Therapies Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Antisense Oligonucleotide Therapies Market Size by Country (2018-2023)
6.4.3 North America Antisense Oligonucleotide Therapies Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Antisense Oligonucleotide Therapies Market Size (2018-2029)
7.2 Europe Antisense Oligonucleotide Therapies Market Size by Type
7.2.1 Europe Antisense Oligonucleotide Therapies Market Size by Type (2018-2023)
7.2.2 Europe Antisense Oligonucleotide Therapies Market Size by Type (2024-2029)
7.2.3 Europe Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
7.3 Europe Antisense Oligonucleotide Therapies Market Size by Application
7.3.1 Europe Antisense Oligonucleotide Therapies Market Size by Application (2018-2023)
7.3.2 Europe Antisense Oligonucleotide Therapies Market Size by Application (2024-2029)
7.3.3 Europe Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
7.4 Europe Antisense Oligonucleotide Therapies Market Size by Country
7.4.1 Europe Antisense Oligonucleotide Therapies Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Antisense Oligonucleotide Therapies Market Size by Country (2018-2023)
7.4.3 Europe Antisense Oligonucleotide Therapies Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Antisense Oligonucleotide Therapies Market Size (2018-2029)
8.2 China Antisense Oligonucleotide Therapies Market Size by Type
8.2.1 China Antisense Oligonucleotide Therapies Market Size by Type (2018-2023)
8.2.2 China Antisense Oligonucleotide Therapies Market Size by Type (2024-2029)
8.2.3 China Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
8.3 China Antisense Oligonucleotide Therapies Market Size by Application
8.3.1 China Antisense Oligonucleotide Therapies Market Size by Application (2018-2023)
8.3.2 China Antisense Oligonucleotide Therapies Market Size by Application (2024-2029)
8.3.3 China Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Antisense Oligonucleotide Therapies Market Size (2018-2029)
9.2 Asia Antisense Oligonucleotide Therapies Market Size by Type
9.2.1 Asia Antisense Oligonucleotide Therapies Market Size by Type (2018-2023)
9.2.2 Asia Antisense Oligonucleotide Therapies Market Size by Type (2024-2029)
9.2.3 Asia Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
9.3 Asia Antisense Oligonucleotide Therapies Market Size by Application
9.3.1 Asia Antisense Oligonucleotide Therapies Market Size by Application (2018-2023)
9.3.2 Asia Antisense Oligonucleotide Therapies Market Size by Application (2024-2029)
9.3.3 Asia Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
9.4 Asia Antisense Oligonucleotide Therapies Market Size by Region
9.4.1 Asia Antisense Oligonucleotide Therapies Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Antisense Oligonucleotide Therapies Market Size by Region (2018-2023)
9.4.3 Asia Antisense Oligonucleotide Therapies Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Type
10.2.1 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Application
10.3.1 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country
10.4.1 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Details
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Introduction
11.1.4 Ionis Pharmaceuticals Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.1.5 Ionis Pharmaceuticals Recent Developments
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Details
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Introduction
11.2.4 Sarepta Therapeutics Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.2.5 Sarepta Therapeutics Recent Developments
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Company Details
11.3.2 Nippon Shinyaku Business Overview
11.3.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Introduction
11.3.4 Nippon Shinyaku Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.3.5 Nippon Shinyaku Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Without GalNAc-conjugated
1.2.3 With GalNAc-conjugated
1.3 Market by Application
1.3.1 Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Antisense Oligonucleotide Therapies Market Perspective (2018-2029)
2.2 Global Antisense Oligonucleotide Therapies Growth Trends by Region
2.2.1 Antisense Oligonucleotide Therapies Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Antisense Oligonucleotide Therapies Historic Market Size by Region (2018-2023)
2.2.3 Antisense Oligonucleotide Therapies Forecasted Market Size by Region (2024-2029)
2.3 Antisense Oligonucleotide Therapies Market Dynamics
2.3.1 Antisense Oligonucleotide Therapies Industry Trends
2.3.2 Antisense Oligonucleotide Therapies Market Drivers
2.3.3 Antisense Oligonucleotide Therapies Market Challenges
2.3.4 Antisense Oligonucleotide Therapies Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Revenue Antisense Oligonucleotide Therapies by Players
3.1.1 Global Antisense Oligonucleotide Therapies Revenue by Players (2018-2023)
3.1.2 Global Antisense Oligonucleotide Therapies Revenue Market Share by Players (2018-2023)
3.2 Global Antisense Oligonucleotide Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Antisense Oligonucleotide Therapies, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Antisense Oligonucleotide Therapies Market Concentration Ratio
3.4.1 Global Antisense Oligonucleotide Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense Oligonucleotide Therapies Revenue in 2022
3.5 Global Key Players of Antisense Oligonucleotide Therapies Head office and Area Served
3.6 Global Key Players of Antisense Oligonucleotide Therapies, Product and Application
3.7 Global Key Players of Antisense Oligonucleotide Therapies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 ANTISENSE OLIGONUCLEOTIDE THERAPIES BREAKDOWN DATA BY TYPE
4.1 Global Antisense Oligonucleotide Therapies Historic Market Size by Type (2018-2023)
4.2 Global Antisense Oligonucleotide Therapies Forecasted Market Size by Type (2024-2029)
5 ANTISENSE OLIGONUCLEOTIDE THERAPIES BREAKDOWN DATA BY APPLICATION
5.1 Global Antisense Oligonucleotide Therapies Historic Market Size by Application (2018-2023)
5.2 Global Antisense Oligonucleotide Therapies Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Antisense Oligonucleotide Therapies Market Size (2018-2029)
6.2 North America Antisense Oligonucleotide Therapies Market Size by Type
6.2.1 North America Antisense Oligonucleotide Therapies Market Size by Type (2018-2023)
6.2.2 North America Antisense Oligonucleotide Therapies Market Size by Type (2024-2029)
6.2.3 North America Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
6.3 North America Antisense Oligonucleotide Therapies Market Size by Application
6.3.1 North America Antisense Oligonucleotide Therapies Market Size by Application (2018-2023)
6.3.2 North America Antisense Oligonucleotide Therapies Market Size by Application (2024-2029)
6.3.3 North America Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
6.4 North America Antisense Oligonucleotide Therapies Market Size by Country
6.4.1 North America Antisense Oligonucleotide Therapies Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Antisense Oligonucleotide Therapies Market Size by Country (2018-2023)
6.4.3 North America Antisense Oligonucleotide Therapies Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 EUROPE
7.1 Europe Antisense Oligonucleotide Therapies Market Size (2018-2029)
7.2 Europe Antisense Oligonucleotide Therapies Market Size by Type
7.2.1 Europe Antisense Oligonucleotide Therapies Market Size by Type (2018-2023)
7.2.2 Europe Antisense Oligonucleotide Therapies Market Size by Type (2024-2029)
7.2.3 Europe Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
7.3 Europe Antisense Oligonucleotide Therapies Market Size by Application
7.3.1 Europe Antisense Oligonucleotide Therapies Market Size by Application (2018-2023)
7.3.2 Europe Antisense Oligonucleotide Therapies Market Size by Application (2024-2029)
7.3.3 Europe Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
7.4 Europe Antisense Oligonucleotide Therapies Market Size by Country
7.4.1 Europe Antisense Oligonucleotide Therapies Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Antisense Oligonucleotide Therapies Market Size by Country (2018-2023)
7.4.3 Europe Antisense Oligonucleotide Therapies Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 CHINA
8.1 China Antisense Oligonucleotide Therapies Market Size (2018-2029)
8.2 China Antisense Oligonucleotide Therapies Market Size by Type
8.2.1 China Antisense Oligonucleotide Therapies Market Size by Type (2018-2023)
8.2.2 China Antisense Oligonucleotide Therapies Market Size by Type (2024-2029)
8.2.3 China Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
8.3 China Antisense Oligonucleotide Therapies Market Size by Application
8.3.1 China Antisense Oligonucleotide Therapies Market Size by Application (2018-2023)
8.3.2 China Antisense Oligonucleotide Therapies Market Size by Application (2024-2029)
8.3.3 China Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia Antisense Oligonucleotide Therapies Market Size (2018-2029)
9.2 Asia Antisense Oligonucleotide Therapies Market Size by Type
9.2.1 Asia Antisense Oligonucleotide Therapies Market Size by Type (2018-2023)
9.2.2 Asia Antisense Oligonucleotide Therapies Market Size by Type (2024-2029)
9.2.3 Asia Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
9.3 Asia Antisense Oligonucleotide Therapies Market Size by Application
9.3.1 Asia Antisense Oligonucleotide Therapies Market Size by Application (2018-2023)
9.3.2 Asia Antisense Oligonucleotide Therapies Market Size by Application (2024-2029)
9.3.3 Asia Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
9.4 Asia Antisense Oligonucleotide Therapies Market Size by Region
9.4.1 Asia Antisense Oligonucleotide Therapies Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Antisense Oligonucleotide Therapies Market Size by Region (2018-2023)
9.4.3 Asia Antisense Oligonucleotide Therapies Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 MIDDLE EAST, AFRICA, AND LATIN AMERICA
10.1 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Type
10.2.1 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Application
10.3.1 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country
10.4.1 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 KEY PLAYERS PROFILES
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Details
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Introduction
11.1.4 Ionis Pharmaceuticals Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.1.5 Ionis Pharmaceuticals Recent Developments
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Details
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Introduction
11.2.4 Sarepta Therapeutics Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.2.5 Sarepta Therapeutics Recent Developments
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Company Details
11.3.2 Nippon Shinyaku Business Overview
11.3.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Introduction
11.3.4 Nippon Shinyaku Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.3.5 Nippon Shinyaku Recent Developments
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Without GalNAc-conjugated
Table 3. Key Players of With GalNAc-conjugated
Table 4. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Antisense Oligonucleotide Therapies Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Antisense Oligonucleotide Therapies Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Antisense Oligonucleotide Therapies Market Share by Region (2018-2023)
Table 8. Global Antisense Oligonucleotide Therapies Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Antisense Oligonucleotide Therapies Market Share by Region (2024-2029)
Table 10. Antisense Oligonucleotide Therapies Market Trends
Table 11. Antisense Oligonucleotide Therapies Market Drivers
Table 12. Antisense Oligonucleotide Therapies Market Challenges
Table 13. Antisense Oligonucleotide Therapies Market Restraints
Table 14. Global Antisense Oligonucleotide Therapies Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Antisense Oligonucleotide Therapies Revenue Share by Players (2018-2023)
Table 16. Global Top Antisense Oligonucleotide Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide Therapies as of 2022)
Table 17. Global Antisense Oligonucleotide Therapies Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Antisense Oligonucleotide Therapies Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Antisense Oligonucleotide Therapies, Headquarters and Area Served
Table 20. Global Key Players of Antisense Oligonucleotide Therapies, Product and Application
Table 21. Global Key Players of Antisense Oligonucleotide Therapies, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2018-2023)
Table 25. Global Antisense Oligonucleotide Therapies Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2024-2029)
Table 27. Global Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Antisense Oligonucleotide Therapies Revenue Share by Application (2018-2023)
Table 29. Global Antisense Oligonucleotide Therapies Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Antisense Oligonucleotide Therapies Revenue Share by Application (2024-2029)
Table 31. North America Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Antisense Oligonucleotide Therapies Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Antisense Oligonucleotide Therapies Market Size by Application (2024-2029) & (US$ Million)
Table 35. North America Antisense Oligonucleotide Therapies Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Antisense Oligonucleotide Therapies Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Antisense Oligonucleotide Therapies Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Antisense Oligonucleotide Therapies Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Antisense Oligonucleotide Therapies Market Size by Application (2024-2029) & (US$ Million)
Table 42. Europe Antisense Oligonucleotide Therapies Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Antisense Oligonucleotide Therapies Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Antisense Oligonucleotide Therapies Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Antisense Oligonucleotide Therapies Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Antisense Oligonucleotide Therapies Market Size by Application (2024-2029) & (US$ Million)
Table 49. Asia Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Antisense Oligonucleotide Therapies Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Antisense Oligonucleotide Therapies Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Antisense Oligonucleotide Therapies Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Antisense Oligonucleotide Therapies Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Antisense Oligonucleotide Therapies Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Application (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country (2024-2029) & (US$ Million)
Table 63. Ionis Pharmaceuticals Company Details
Table 64. Ionis Pharmaceuticals Business Overview
Table 65. Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product
Table 66. Ionis Pharmaceuticals Revenue in Antisense Oligonucleotide Therapies Business (2018-2023) & (US$ Million)
Table 67. Ionis Pharmaceuticals Recent Developments
Table 68. Sarepta Therapeutics Company Details
Table 69. Sarepta Therapeutics Business Overview
Table 70. Sarepta Therapeutics Antisense Oligonucleotide Therapies Product
Table 71. Sarepta Therapeutics Revenue in Antisense Oligonucleotide Therapies Business (2018-2023) & (US$ Million)
Table 72. Sarepta Therapeutics Recent Developments
Table 73. Nippon Shinyaku Company Details
Table 74. Nippon Shinyaku Business Overview
Table 75. Nippon Shinyaku Antisense Oligonucleotide Therapies Product
Table 76. Nippon Shinyaku Revenue in Antisense Oligonucleotide Therapies Business (2018-2023) & (US$ Million)
Table 77. Nippon Shinyaku Recent Developments
Table 78. Research Programs/Design for This Report
Table 79. Key Data Information from Secondary Sources
Table 80. Key Data Information from Primary Sources
Table 1. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Without GalNAc-conjugated
Table 3. Key Players of With GalNAc-conjugated
Table 4. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Antisense Oligonucleotide Therapies Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Antisense Oligonucleotide Therapies Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Antisense Oligonucleotide Therapies Market Share by Region (2018-2023)
Table 8. Global Antisense Oligonucleotide Therapies Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Antisense Oligonucleotide Therapies Market Share by Region (2024-2029)
Table 10. Antisense Oligonucleotide Therapies Market Trends
Table 11. Antisense Oligonucleotide Therapies Market Drivers
Table 12. Antisense Oligonucleotide Therapies Market Challenges
Table 13. Antisense Oligonucleotide Therapies Market Restraints
Table 14. Global Antisense Oligonucleotide Therapies Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Antisense Oligonucleotide Therapies Revenue Share by Players (2018-2023)
Table 16. Global Top Antisense Oligonucleotide Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide Therapies as of 2022)
Table 17. Global Antisense Oligonucleotide Therapies Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Antisense Oligonucleotide Therapies Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Antisense Oligonucleotide Therapies, Headquarters and Area Served
Table 20. Global Key Players of Antisense Oligonucleotide Therapies, Product and Application
Table 21. Global Key Players of Antisense Oligonucleotide Therapies, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2018-2023)
Table 25. Global Antisense Oligonucleotide Therapies Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2024-2029)
Table 27. Global Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Antisense Oligonucleotide Therapies Revenue Share by Application (2018-2023)
Table 29. Global Antisense Oligonucleotide Therapies Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Antisense Oligonucleotide Therapies Revenue Share by Application (2024-2029)
Table 31. North America Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Antisense Oligonucleotide Therapies Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Antisense Oligonucleotide Therapies Market Size by Application (2024-2029) & (US$ Million)
Table 35. North America Antisense Oligonucleotide Therapies Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Antisense Oligonucleotide Therapies Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Antisense Oligonucleotide Therapies Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Antisense Oligonucleotide Therapies Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Antisense Oligonucleotide Therapies Market Size by Application (2024-2029) & (US$ Million)
Table 42. Europe Antisense Oligonucleotide Therapies Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Antisense Oligonucleotide Therapies Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Antisense Oligonucleotide Therapies Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Antisense Oligonucleotide Therapies Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Antisense Oligonucleotide Therapies Market Size by Application (2024-2029) & (US$ Million)
Table 49. Asia Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Antisense Oligonucleotide Therapies Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Antisense Oligonucleotide Therapies Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Antisense Oligonucleotide Therapies Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Antisense Oligonucleotide Therapies Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Antisense Oligonucleotide Therapies Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Application (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size by Country (2024-2029) & (US$ Million)
Table 63. Ionis Pharmaceuticals Company Details
Table 64. Ionis Pharmaceuticals Business Overview
Table 65. Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product
Table 66. Ionis Pharmaceuticals Revenue in Antisense Oligonucleotide Therapies Business (2018-2023) & (US$ Million)
Table 67. Ionis Pharmaceuticals Recent Developments
Table 68. Sarepta Therapeutics Company Details
Table 69. Sarepta Therapeutics Business Overview
Table 70. Sarepta Therapeutics Antisense Oligonucleotide Therapies Product
Table 71. Sarepta Therapeutics Revenue in Antisense Oligonucleotide Therapies Business (2018-2023) & (US$ Million)
Table 72. Sarepta Therapeutics Recent Developments
Table 73. Nippon Shinyaku Company Details
Table 74. Nippon Shinyaku Business Overview
Table 75. Nippon Shinyaku Antisense Oligonucleotide Therapies Product
Table 76. Nippon Shinyaku Revenue in Antisense Oligonucleotide Therapies Business (2018-2023) & (US$ Million)
Table 77. Nippon Shinyaku Recent Developments
Table 78. Research Programs/Design for This Report
Table 79. Key Data Information from Secondary Sources
Table 80. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Antisense Oligonucleotide Therapies Market Share by Type: 2022 VS 2029
Figure 3. Without GalNAc-conjugated Features
Figure 4. With GalNAc-conjugated Features
Figure 5. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Antisense Oligonucleotide Therapies Market Share by Application: 2022 VS 2029
Figure 7. Genetic Disease Case Studies
Figure 8. Cancer Case Studies
Figure 9. Cardiovascular Diseases Case Studies
Figure 10. Other Case Studies
Figure 11. Antisense Oligonucleotide Therapies Report Years Considered
Figure 12. Global Antisense Oligonucleotide Therapies Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Antisense Oligonucleotide Therapies Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Antisense Oligonucleotide Therapies Market Share by Region: 2022 VS 2029
Figure 15. Global Antisense Oligonucleotide Therapies Market Share by Players in 2022
Figure 16. Global Top Antisense Oligonucleotide Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide Therapies as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Antisense Oligonucleotide Therapies Revenue in 2022
Figure 18. North America Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
Figure 20. North America Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
Figure 21. North America Antisense Oligonucleotide Therapies Market Share by Country (2018-2029)
Figure 22. United States Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Antisense Oligonucleotide Therapies Market Size YoY (2018-2029) & (US$ Million)
Figure 25. Europe Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
Figure 26. Europe Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
Figure 27. Europe Antisense Oligonucleotide Therapies Market Share by Country (2018-2029)
Figure 28. Germany Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. France Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. U.K. Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Italy Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Russia Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Nordic Countries Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. China Antisense Oligonucleotide Therapies Market Size YoY (2018-2029) & (US$ Million)
Figure 35. China Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
Figure 36. China Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
Figure 37. Asia Antisense Oligonucleotide Therapies Market Size YoY (2018-2029) & (US$ Million)
Figure 38. Asia Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
Figure 39. Asia Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
Figure 40. Asia Antisense Oligonucleotide Therapies Market Share by Region (2018-2029)
Figure 41. Japan Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. South Korea Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. China Taiwan Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Southeast Asia Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. India Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Australia Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size YoY (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
Figure 49. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
Figure 50. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Share by Country (2018-2029)
Figure 51. Brazil Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Mexico Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Turkey Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Israel Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. GCC Countries Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Ionis Pharmaceuticals Revenue Growth Rate in Antisense Oligonucleotide Therapies Business (2018-2023)
Figure 58. Sarepta Therapeutics Revenue Growth Rate in Antisense Oligonucleotide Therapies Business (2018-2023)
Figure 59. Nippon Shinyaku Revenue Growth Rate in Antisense Oligonucleotide Therapies Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Figure 1. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Antisense Oligonucleotide Therapies Market Share by Type: 2022 VS 2029
Figure 3. Without GalNAc-conjugated Features
Figure 4. With GalNAc-conjugated Features
Figure 5. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Antisense Oligonucleotide Therapies Market Share by Application: 2022 VS 2029
Figure 7. Genetic Disease Case Studies
Figure 8. Cancer Case Studies
Figure 9. Cardiovascular Diseases Case Studies
Figure 10. Other Case Studies
Figure 11. Antisense Oligonucleotide Therapies Report Years Considered
Figure 12. Global Antisense Oligonucleotide Therapies Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Antisense Oligonucleotide Therapies Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Antisense Oligonucleotide Therapies Market Share by Region: 2022 VS 2029
Figure 15. Global Antisense Oligonucleotide Therapies Market Share by Players in 2022
Figure 16. Global Top Antisense Oligonucleotide Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide Therapies as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Antisense Oligonucleotide Therapies Revenue in 2022
Figure 18. North America Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
Figure 20. North America Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
Figure 21. North America Antisense Oligonucleotide Therapies Market Share by Country (2018-2029)
Figure 22. United States Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Antisense Oligonucleotide Therapies Market Size YoY (2018-2029) & (US$ Million)
Figure 25. Europe Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
Figure 26. Europe Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
Figure 27. Europe Antisense Oligonucleotide Therapies Market Share by Country (2018-2029)
Figure 28. Germany Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. France Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. U.K. Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Italy Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Russia Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Nordic Countries Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. China Antisense Oligonucleotide Therapies Market Size YoY (2018-2029) & (US$ Million)
Figure 35. China Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
Figure 36. China Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
Figure 37. Asia Antisense Oligonucleotide Therapies Market Size YoY (2018-2029) & (US$ Million)
Figure 38. Asia Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
Figure 39. Asia Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
Figure 40. Asia Antisense Oligonucleotide Therapies Market Share by Region (2018-2029)
Figure 41. Japan Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. South Korea Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. China Taiwan Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Southeast Asia Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. India Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Australia Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Size YoY (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Share by Type (2018-2029)
Figure 49. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Share by Application (2018-2029)
Figure 50. Middle East, Africa, and Latin America Antisense Oligonucleotide Therapies Market Share by Country (2018-2029)
Figure 51. Brazil Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Mexico Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Turkey Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Israel Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. GCC Countries Antisense Oligonucleotide Therapies Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Ionis Pharmaceuticals Revenue Growth Rate in Antisense Oligonucleotide Therapies Business (2018-2023)
Figure 58. Sarepta Therapeutics Revenue Growth Rate in Antisense Oligonucleotide Therapies Business (2018-2023)
Figure 59. Nippon Shinyaku Revenue Growth Rate in Antisense Oligonucleotide Therapies Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
